check_circleStudy Completed

Carcinoma, Non-Small-Cell Lung, Lung Cancer

Dose escalating study with BAY43-9006 with carboplatin, paclitaxel and bevacizumab in untreated stage IIIb non-small cell lung cancer (NSCLC)

Trial purpose

To determine the tolerability, maximum tolerated dose and pharmacokinetics of this drug.

Key Participants Requirements

Sex

Both

Age

18 Years

Trial summary

Enrollment Goal
33
Trial Dates
July 2006 - October 2011
Phase
Phase 1
Could I Receive a placebo
No
Products
Nexavar (Sorafenib, BAY43-9006)
Accepts Healthy Volunteer
No

Where to participate

StatusInstitutionLocation
Completed
M. D. Anderson Cancer Center - University of TexasHouston, 77030, United States
Completed
Mayo Clinic - RochesterRochester, 55905, United States

Primary Outcome

  • The primary objective of this study is to define the safety profile and maximum tolerated dose (MTD) of BAY43-9006 (sorafenib) administered in combination with, carboplatin, paclitaxel and bevacizumab
    date_rangeTime Frame:
    2 years
    enhanced_encryption
    Safety Issue:
    yes

Secondary Outcome

  • The secondary objectives include evaluation of pharmacokinetics, biomarkers, pharmacodynamics and tumor response of patients treated with BAY43-9006 (sorafenib) in combination with bevacizumab, paclitaxel and carboplatin
    date_rangeTime Frame:
    2 years
    enhanced_encryption
    Safety Issue:
    yes

Trial design

Study of BAY43-9006 (sorafenib) in combination with carboplatin, paclitaxel and bevacizumab in previously untreated patients with Stage IIIB (with malignant pleural effusions) or Stage IV non-small cell lung cancer (NSCLC)
Trial Type
Interventional
Intervention Type
Drug
Trial Purpose
Basic Science
Allocation
Non-randomized
Blinding
Open Label
Assignment
Parallel Assignment
Trial Arms
6